Charles Carter - Feb 14, 2024 Form 3 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (CERO)

Signature
/s/ Charles Carter
Stock symbol
CERO
Transactions as of
Feb 14, 2024
Transactions value $
$0
Form type
3
Date filed
2/16/2024, 07:28 PM
Previous filing
Jan 18, 2022
Next filing
Mar 27, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CERO Series A Convertible Preferred Stock Feb 14, 2024 Common Stock 5K $10.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney. Effective immediately after the Effective Time as defined in that certain Business Combination Agreement dated as of June 4, 2023, as amended, by and among the Issuer (f/k/a Phoenix Biotech Acquisition Corp.), CERo Therapeutics, Inc. and PBCE Merger Sub, Inc., the reporting person became an executive officer of the Issuer.